Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Abliva: Potentially faster to market

Gergana Almquist

2020-09-11

10:49

Redeye maintains its fair value of Abliva at SEK 1.4 per share. Optimism around its main asset, KL1333, has increased, but there are still many unknowns concerning clinical outcomes and financing.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Premium Plan required to unlock